ClinicalTrials.Veeva

Menu

Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor (GLUCORRECTOR)

U

University Hospital, Strasbourg, France

Status

Completed

Conditions

Cystic Fibrosis Homozygous for Phe 508 Del CFTR
Glucose Intolerance or Newly Diagnosis Diabetes

Treatments

Drug: Lumacaftor-Ivacaftor treatment

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Cystic Fibrosis related diabetes (CFRD), a major factor of morbid-mortality in CF, is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years.

At the physiopathology level, insulin secretion is determinant in the glucose tolerance abnormalities in CF. Indeed insulin secretion is dependent of the CFTR activity at the beta cell surface and inhibition of CFTR leads to a decrease in insulin secretion.

Recently, the combination of the lumacaftor, a CFTR corrector, with Ivacaftor, a CFTR potentiator, was studied in patient with CF homozygous for the Phe508 del CFTR mutation patients and showed an improvement of the respiratory state in comparison with the placebo group.

These data suggests that lumacaftor in combination with ivacaftor in targeting CFTR action may have an early impact on the insulin-secretion and consequently on the glucose tolerance.

Enrollment

55 patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • patients with CF homozygous for the Phe508del CFTR mutation aged 12 years and over
  • Combined Lumacaftor-Ivacaftor treatment scheduled or already started
  • glucose intolerance in OGTT (ADA criteria) or newly diabetes diagnosed at the OGTT (ADA criteria) or diabetic patients with insulin requirement ≤ 0.3 unit / kg / day or without insulin treatment
  • signed informed consent of patient and of one parent OR legal representative for minor subject

Exclusion criteria

  • hypersensitivity to the active substances or to any of the excipients of Lumactfor -Ivacaftor
  • lung and/or liver transplant patient
  • Known diabetes with insulin treatment > 0.3 unit / kg / day
  • patient pregnant or wishing to pregnancy

Trial design

55 participants in 1 patient group

Patient
Description:
Patient with cystic fibrosis homozygous for Phe 508 del CFTR having a glucose intolerance or newly diagnosis diabetes
Treatment:
Drug: Lumacaftor-Ivacaftor treatment

Trial contacts and locations

13

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems